Riociguat in patients with chronic thromboembolic pulmonary hypertension

• Verfasst von: McLaughlin, Vallerie V. [VerfasserIn]
• Verfasst von: Grünig, Ekkehard [VerfasserIn]
• Titel: Riociguat in patients with chronic thromboembolic pulmonary hypertension
• Titelzusatz: results from an early access study
• Verf.angabe: Vallerie V. McLaughlin, Pavel Jansa, Jens E. Nielsen-Kudsk, Michael Halank, Gérald Simonneau, Ekkehard Grünig, Silvia Ulrich, Stephan Rosenkranz, Miguel A. Gómez Sánchez, Tomás Pulido, Joanna Pepke-Zaba, Joan Albert Barberá, Marius M. Hoeper, Jean-Luc Vachiéry, Irene Lang, Francine Carvalho, Christian Meier, Katharina Mueller, Sylvia Nikkho and Andrea M. D’Armini
• E-Jahr: 2017
• Jahr: 28 December 2017
• Umfang: 9 S.
• Fussnoten: Gesehen am 16.11.2018
• Titel Quelle: Enthalten in: BMC pulmonary medicine
• Ort Quelle: London : BioMed Central, 2001
• Jahr Quelle: 2017
• Band/Heft Quelle: 17(2017), Artikel-ID 216
• ISSN Quelle: 1471-2466
• DOI: doi:10.1186/s12890-017-0563-7
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1583782303

Abstract

Following positive results from the Phase III CHEST-1 study in patients with inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), the Phase IIIb CTEPH early access study (EAS) was designed to assess the safety and tolerability of riociguat in real-world clinical practice, as well as to provide patients with early access to riociguat before launch. Riociguat is approved for the treatment of inoperable and persistent/recurrent CTEPH.